PM-477 

First-in-class synthetic lysin

Medical need:

Bacterial vaginosis

image49.png
phagomedElement 22300.png
phagomedElement 22300.png
phagomedElement.png
phagomedElement 1.png

High efficacy,

high precision

Pathogen:

Gardnerella spp.

Patient population:

1 in 4 women (aged 15-49) p.a. globally

Recurrence:

60% within 6 months

Current standard-of-care:

Broad-spectrum antibiotics (acute) and long-term suppressive antibiotics (chronic)

Cleaving domain

PM-477 has a cleaving domain. After it binds to the cell wall, it lyses it. The cell bursts and the bacteria die.

image27_edited.png
image28_edited.png

Binding domain

PM-477 has a Gardnerella specific binding domain. It only binds to the cell wall of Gardnerella bacteria. It is specific.

PM-477

Target pathogen: Gardnerella spp.

Indication: recurrent bacterial vaginosis

Discovery

Lead optimization

Pre-clinical

Phase I

Phase II

pm-477 thumbnail

Read our Publication in Pathogens

The first publication detailing PM-477 is now available.  

Scientific Advisory Board

image18.jpg

Prof. Dr. med. Werner Mendling

image26.png

Prof. Dr. Christina Muzny

ClJIsbPw.jpeg

Dr. Gregory Resch

image27-2.png

Prof. Dr. Jane Schwebke

image23.png

Prof. Dr. Jack Sobel

image21.jpg

PD Dr. Alexander Swidsinski

image20.jpeg

Prof. Dr. Mario Vaneechoutte